BioStock: Curasight caps 2024 with financing push

Reporting the fourth quarter, financing is high on the agenda for danish Curasight. With the prostate cancer study ongoing with uTRACE, the company targets mid 2025 for the start of the first clinical study with the thrapeutics platform uTREAT, in brain cancer. BioStock reached out to CEO Ulrich Krasilnikoff to learn more.

Read the full interview with Ulrich Krasilnikoff at biostock.se:

https://www.biostock.se/en/2025/02/curasight-caps-2024-with-financing-push/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/